Work

A phase 1, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 x CD3 DART molecule, in patients with relapsed/refractory metastatic colorectal carcinoma.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps3628

Authors: John D. Powderly, Herbert Hurwitz, David P. Ryan, Daniel A. Laheru, Naimish B. Pandya, Joanna Lohr, Paul A. Moore, Ezio Bonvini, Jon M. Wigginton, Todd S. Crocenzi

Institutions: Carolina BioOncology Institute, Duke Medical Center, Massachusetts General Hospital, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, MacroGenics (United States), Providence Portland Medical Center

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889938040

Cites:

Cited by: 7

Related to: 10